pursuant to the applicable tariff, notwithstanding demand for payment.

This proceeding has been assigned to Administrative Law Judge Charles E. Morgan ("Presiding Officer"). Hearing in this matter, if any is held, shall commence within the time limitations prescribed in 46 CFR 502.61. The hearing shall include oral testimony and cross-examination in the discretion of the Presiding Officer only upon proper showing that there are genuine issues of material fact that cannot be resolved on the basis of sworn statements, affidavits, depositions, or other documents or that the nature of the matter in issue is such that an oral hearing and cross-examination are necessary for the development of an adequate record. Pursuant to the further terms of 46 CFR 502.61, the initial decision of the Presiding Officer in this proceeding shall be issued by February 3, 1993, and the final decision of the Commission shall be issued by June 3, 1993.

Joseph C. Polking,

Secretary.

[FR Doc. 92-2966 Filed 2-6-92; 8:45 am]

BILLING CODE 6730-01-M

FEDERAL RESERVE SYSTEM

Carlos Salman, et al.; Change in Bank Control Notice; Acquisition of Shares of Banks or Bank Holding Companies

The notificant listed below has applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notice is available for immediate inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for the notice or to the offices of the Board of Governors. Comments must be received not later than March 3, 1992.

A. Federal Reserve Bank of Atlanta (Robert E. Heck, Vice President) 104 Marietta Street, NW., Atlanta, Georgia 30303:

1. Carlos Salman, Miami, Florida; to acquire an additional 11.30 percent of the voting shares of Terrabank Holding Corporation, Miami, Florida, for a total of 20.57 percent, and thereby indirectly acquire Terrabank, N.A., Miami, Florida.

Board of Governors of the Federal Reserve System, February 3, 1992.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 92-2986 Filed 2-6-92; 8:45 am]

BILLING CODE 6210-01-F

U.S.B. Holding Co., Inc., et al.; Formations of; Acquisitions by; and Mergers of Bank Holding Companies

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than March 3, 1992.

A. Federal Reserve Bank of New York (William L. Rutledge, Vice President) 33 Liberty Street, New York, New York 10045:

1. U.S.B. Holding Company, Inc., Nanuet, New York; to acquire 26 percent of the voting shares of New Milford Bank and Trust Company, Inc., New Milford, Connecticut.

B. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. F & M National Corporation, Winchester, Virginia; to acquire 100 percent of the voting shares of Farmers & Merchants Bank of Keyser, Keyser, West Virginia.

C. Federal Reserve Bank of Atlanta (Robert E. Heck, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303:

1. Villages Bancorporation, Inc., Lady Lake, Florida; to become a bank holding company by acquiring 100 percent of the voting shares of First Bank of the Villages, Lady Lake, Florida.

D. Federal Reserve Bank of Chicago (David S. Epstein, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. Fairmount Banking Company, Fairmount, Indiana; to become a bank holding company by acquiring 100 percent of the voting shares of The Fairmount State Bank, Fairmount, Indiana.

Board of Governors of the Federal Reserve System, February 3, 1992.

Jennifer J. Johnson,

Associate Secretary of the Board

[FR Doc. 92-2987 Filed 2-6-92; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

[ATSDR-47]

Procedure for Conducting Voluntary Research

AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR), Public Health Service (PHS), Department of Health and Human Services (HHS)

ACTION: Notice.

SUMMARY: This notice announces the procedure for volunteering to conduct research as part of the ATSDR Substance-Specific Applied Research Program authorized by the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), as amended. The voluntary research will be conducted by the private sector to fill priority data needs for hazardous substances that are the subjects of the ATSDR Toxicological Profiles. To date, the priority data needs for 38 hazardous substances have been identified and announced by ATSDR in the **Federal Register** (56 FR 52178) on October 17, 1991. As part of this procedure for conducting voluntary research, the Agency has developed a model agreement, Memorandum of Understanding (MOU), that will be signed by ATSDR and the interested private sector organization(s) (hereinafter referred to as the Company, although multiple companies or a consortium may be signatories to a single MOU) prior to the initiation of the voluntary research. The public is invited to comment on this procedure for conducting voluntary research, and the model MOU.

DATES: The ATSDR considers this voluntary research effort to be of significant importance to the continuing development of the Substance-Specific Applied Research Program. Therefore, public comments concerning this Federal Register notice will be accepted throughout the Agency's involvement with voluntary research.

ADDRESSES: Comments on this notice should bear the docket control number ATSDR-47 and should be submitted to the Division of Toxicology, Research Implementation Branch, Agency for Toxic Substances and Disease Registry, Mailstop E-29, 1600 Clifton Road NE., Atlanta, Georgia 30333. Requests for a copy of the model Memorandum of Understanding should be addressed similarly.

Comments on this notice will be available for public inspection at the Agency for Toxic Substances and Disease Registry, Building 33, Executive Park Drive, Atlanta, Georgia (not a mailing address), from 8 a.m. until 4:30 p.m., Monday through Friday, except for legal holidays.

FOR FURTHER INFORMATION CONTACT: The Division of Toxicology, Research Implementation Branch, Agency for Toxic Substances and Disease Registry, Mailstop E-29, 1600 Clifton Road NE., Atlanta, Georgia 30333. Telephone: 404-639-6015 or FTS 236-6015.

SUPPLEMENTARY INFORMATION:

Background

The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) (42 U.S.C. 9604(i)), as amended by the Superfund Amendments and Reauthorization Act (SARA) (Pub. L. 99-499), requires that ATSDR: (1) Develop jointly with the Environmental Protection Agency (EPA) a list of hazardous substances found at National Priorities List (NPL) sites, (in order of priority), (2) prepare Toxicological Profiles of these substances, and (3) assure the initiation of a research program to fill identified data needs associated with the substances.

The identification of the priority data needs for 38 priority hazardous substances was described in the Federal Register (October 17, 1991, 56 FR 52178), public comments were invited, and Companies were invited to volunteer to conduct research to fill specific priority data needs during the public comment period for that notice. Future Federal Register notices will announce (1) the final list of priority data needs for the 38 hazardous substances after public comments on these priority data needs have been addressed, (2) a second call for voluntarism to conduct research to fill priority data needs, and (3) the names of Companies that have volunteered to fill specific priority data needs.

The major purpose of this ATSDR Applied Research Program is to supplement the substance-specific informational needs of the public and scientific community; and to supply necessary information for conducting comprehensive public health assessments for populations living in the vicinity of hazardous waste sites. This program will also provide data that can be generalized to other substances or areas of science, including risk assessments of chemicals, thus creating a scientific base for filling a broader range of data needs.

Procedure for Conducting Voluntary Research

CERCLA, as amended in section 104(i)(5)(D), states that it is the sense of Congress that the costs for conducting this research program be borne by the manufacturers and processors of the hazardous substances under the Toxic Substances Control Act (TSCA) and registrants under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), or by cost recovery from responsible parties under CERCLA. To effectuate this statutory intent, the ATSDR has developed a plan whereby portions of this CERCLA Substance-Specific Applied Research Program will be conducted via regulatory mechanisms (TSCA/FIFRA), private sector voluntarism, and through the direct use of CERCLA funds.

ATSDR intends to enter into voluntary research projects in ways that lead only to high quality scientific work. This necessitates peer review of study protocols and results consistent with CERCLA section 104(i)(13). CERCLA requires the peer review panel to consist of three to seven peer reviewers who (a) are selected by the Administrator of ATSDR, (b) are disinterested scientific experts, (c) have a reputation for scientific objectivity, and (d) who lack institutional ties with any person involved in the conduct of the study or research under review.

The ATSDR is aware of concerns within some segments of the public regarding voluntary research conducted by Companies with vested interests in the research. To this end, the Agency encourages the public to comment on ATSDR's procedure for conducting voluntary research in this notice. Additionally, for each research project conducted voluntarily, the MOU (signed by ATSDR and the interested Company), the ATSDR approved study plan, peer reviewers' comments, and the final research report will be available for public inspection at the location and times indicated in the **ADDRESSES** section of this notice.

The ATSDR encourages Companies to volunteer to conduct research on priority data needs that were announced in the Federal Register notice "Identification of Priority Data Needs for 38 Priority Hazardous Substances" (October 17, 1991, 56 FR 52178) and on priority data needs to be subsequently announced by the Agency. Interested Companies are asked to submit concept proposals (1-2 pages, not detailed protocols) during the October 17, 1991-January 15, 1992 public comment period for the above-mentioned notice, and for subsequent Federal Register notices. The concept proposal should include (1) the name of the interested Company, (2) the specific priority data need(s) to be filled, (3) a summary of the Company's experience in conducting research similar to that in the concept proposal, and (4) a statement about the laboratory and other resource capabilities for conducting the proposed research. Interested Companies may submit concept proposals that address substance-specific data needs or, where appropriate, concept proposals for research that will provide information relevant to classes of chemical substances or which may be generalized to other areas of science.

A tri-agency review committee comprised of scientists from ATSDR, the National Toxicology Program (NTP), and the EPA will review these concept proposals. The committee, chaired by the Director of the Division of Toxicology, ATSDR, is charged with coordinating and assuring the appropriate evaluation of research conducted to fill priority data needs of ATSDR's priority hazardous substances relevant to the objectives of CERCLA, as amended. The principal responsibilities of the committee are to (1) provide a forum to discuss substance-specific research activities being carried out via TSCA/FIFRA, private sector voluntarism, or CERCLA funds, (2) coordinate knowledge of research activities to avoid duplication of research being conducted in other programs and under other authorities, and (3) maintain a scheduled forum that provides an overall review of the ATSDR Superfund Applied Research Program. Based on the review committee's recommendations, ATSDR will determine which, and how, specific voluntary research projects will be pursued with volunteering Companies. In instances where volunteered research initiatives are considered by the tri-

agency committee to be more appropriate for EPA response. EPA may negotiate directly with the interested Company.

If ATSDR decides to pursue a specific voluntary research project submitted in a concept proposal by a Company, the Agency will enter into a MOU with the interested Company, or where appropriate, a single MOU will be entered into with multiple Companies. ATSDR recognizes that two or more companies or a consortium of interested firms may elect to enter into collaborative efforts in pursuing one or more concept proposals. Following the signing of the MOU and prior to the initiation of the research, the interested Company will negotiate with ATSDR to agree upon an approved study plan including testing protocols. The content of the MOU is described below.

(1) Identification of the party or parties comprising the Company which enters into the MOU—this section consists of the name and address of each party responsible for the conduct of the research.

(2) Identification of the substance(s) subject to research requirements under the MOU—this section consists of the name and Chemical Abstract Service (CAS) Number of the chemical substance(s) that is the subject of the MOU. The chemical substance(s) to be tested shall be as pure as reasonably can be attained. Alternate language will be substituted when the subject of the research is a human population, as in epidemiologic studies.

(3) Identification of the effects or characteristics for which research is to be conducted—in this section, the health effects, environmental fate or other characteristics for which research is to be conducted under the MOU shall be listed.

(4) Schedule for submission of study plans, initiation of research and submission of interim and final reports—the Company shall submit to ATSDR a study plan for each test six weeks after signing the MOU. The study plan shall include test protocols and a schedule with reasonable timetable and deadlines for initiation and completion of each test and submission of interim and final reports. The test protocols will be reviewed by an ATSDR-appointed peer review panel. If ATSDR disapproves the study plan, it will inform the Company of the deficiencies of the plan. The Company may request reconsideration of the study plan, resubmit a modified study plan, or elect to terminate the MOU with no further obligation of either party under the MOU. In the event that the Company resubmits a modified study plan and ATSDR disapproves it, the Agency may elect to terminate the MOU.

The starting date of the research project may be negotiated depending on the type of research being conducted. However, as a general guideline, the research effort shall be initiated within eight weeks of the approval of the study plan and attendant test protocols. Written notification of the starting date of the test will be submitted to ATSDR by the Company. The completion date of the study will be established from the approved study plan. Interim progress reports shall be submitted to ATSDR within six months after the initiation of testing and thereafter within six months after submission of each previous interim report. The final report on the results of testing shall be submitted to ATSDR no more than 20 weeks following the end of the study. ATSDR acceptance of the final report will be contingent upon approval by ATSDR following the peer reviewers' recommendations, consistent with CERCLA section 104(i)(13) peer review requirements. All results of research conducted pursuant to the MOU and all supporting data associated with the research report will be provided to ATSDR and made available by the Agency to the public as part of its implementation of sections 104(i) (3) and (5) of CERCLA. Final reports will not be accepted if the data is designated Confidential Business Information (CBI) or otherwise restricted from public disclosure.

(5) Modifications of study plans, guidelines, and schedules—if a Company intends to modify a study plan, protocol, or schedule that was approved by ATSDR, it must notify ATSDR in writing of the proposed modifications and reasons therefor. If ATSDR approves of the modifications, the time schedule established for completion of the tests shall be re-negotiated and appended to the existing MOU. If ATSDR disapproves the Company's request and the Company does not accept ATSDR's decision to disapprove the modified study plan, the Company may terminate the MOU.

(6) Observance of Good Laboratory Practices—all research agreed to in the MOU shall be conducted in accordance with the Good Laboratory Practice (GLP) standards codified in 40 CFR 792, to the extent that such GLP standards apply. Should the Company's Good Epidemiology Practices be relevant to a research project, those Practices should be affixed to the study protocol.

(7) Inspections—the Company shall ensure that an authorized employee of ATSDR is permitted, at reasonable times and in a reasonable manner, to (i) inspect any research or testing facility that is conducting research pursuant to the MOU, and (ii) inspect (and in the case of records, copy) any records and specimens required to be maintained in connection with research performed pursuant to the MOU.

(8) Submission and publication of data—all data and reports submitted to ATSDR pursuant to the MOU shall be sent to ATSDR, in duplicate, at the address indicated in the **ADDRESSES** section. Acceptance of the final report is contingent upon approval by ATSDR following the peer reviewers' recommendations, consistent with CERCLA peer review requirements. The Company maintains all rights to publication of data and results, however all results of research conducted pursuant to the MOU and all supporting data associated with the final research report will be provided to ATSDR and made available by the Agency to the public as part of its implementation of Section 104(i)(5) of CERCLA. The final report will not be accepted by ATSDR if the data is designated Confidential Business Information (CBI) or is otherwise restricted from public disclosure.

(9) Payments of costs and expenses—each company shall agree to pay all costs, direct and indirect, associated with the research programs and which are not considered part of ATSDR's administrative costs.

(10) Events constituting a breach of the MOU—Failure by the Company to:

(a) Submit a study plan that receives ATSDR's approval following the peer reviewers, recommendations;

(b) Initiate any test agreed to in the MOU by the date established pursuant to the MOU;

(c) Adhere to GLP standards, established test procedures or accepted practices of good science to the extent that these standards and practices apply;

(d) Submit any interim report required under the MOU by the date established pursuant to the MOU; or

(e) Submit any final report that receives ATSDR's approval following peer review conducted by the Agency, shall constitute a breach of the MOU. In the event of a breach, ATSDR will not impose any claim to damages, but at the Agency's discretion may terminate the MOU.

(11) Termination—since the MOU is entered into voluntarily by ATSDR and the Company, termination by ATSDR is not considered reviewable agency action pursuant to the Administrative Procedure Act or any other applicable Federal law, and there will be no appeal

process beyond that set out in the MOU. The Company may elect to terminate the MOU at any time.

(12) Statutory compliance—consistent with section 104(i)(12) of CERCLA, as amended (42 U.S.C. 9612), nothing in the MOU shall be construed to delay or otherwise affect or impair the authority of the President, the Administrator of ATSDR or the Administrator of EPA to exercise any of their authority under any other provision of law, including TSCA and FIFRA, or the response and abatement authorities of CERCLA.

The results of the research conducted via this ATSDR Substance-Specific Applied Research Program will be used for public health assessment purposes and to reassess ATSDR's substance-specific priority data needs. It is the intention of the Agency, at this time, to re-evaluate the priority data needs for the listed hazardous substances every three years.

Dated: February 3, 1992.

Walter R. Dowdle,

Acting Administrator, Agency for Toxic Substances and Disease Registry.

[FR Doc. 92-2978 Filed 2-6-92; 8:45 am]

BILLING CODE 4160-70-M

Alcohol, Drug Abuse, and Mental Health Administration

Suspension Lifted; Laboratory Again Meets Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: National Institute on Drug Abuse, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services notifies Federal Agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (53 FR 11986) dated April 11, 1988. The following laboratory's certification to engage in urine drug testing for Federal Agencies was suspended on October 15, 1991 (56 FR 54582, October 22, 1991) and was reinstated effective February 4, 1992.

HealthCare/Preferred Laboratories, 24451 Telegraph Road, Southfield, MI 48034, 800-225-9414 (outside MI), 800-328-4142 (inside MI).

FOR FURTHER INFORMATION CONTACT: Mona W. Brown, Press Officer, National Institute on Drug Abuse, room 10-A-39, 5600 Fishers Lane, Rockville, Maryland 20857; Telephone (301)-443-6245.

Richard A. Millstein,

Acting Director, National Institute on Drug Abuse.

[FR Doc. 92-3085 Filed 2-6-92; 8:45 am]

BILLING CODE 4160-20-M

National Institute of Mental Health; Meetings

Pursuant to Public Law 92-463, notice is hereby given of the meetings of the advisory committees of the National Institute of Mental Health for February/March 1992.

The initial review groups will be performing review of applications for Federal assistance; therefore, portions of these meetings will be closed to the public as determined by the Administrator, ADAMHA, in accordance with 5 U.S.C. 552b(c)(6) and 5 U.S.C. app. 2 10(d).

Summaries of the meetings and rosters of committee members may be obtained from: Ms. Joanna L. Kieffer, NIMH Committee Management Officer, Alcohol, Drug Abuse, and Mental Health Administration, Parklawn Building, room 9-105, 5600 Fishers Lane, Rockville, MD 20857 (Telephone: 301-443-4333).

Substantive program information may be obtained from the contacts whose names, room numbers, and telephone numbers are listed below.

Committee Name: Mental Health Small Business Research Review Committee.
Meeting Date: March 2-3, 1992.
Place: Washington Marriott, 1221 22nd Street, NW, Washington, DC 20037.
Open: March 2, 9-10:30 a.m.
Closed: Otherwise.
Contact: Gloria Levin, room 9C-14, Parklawn Building, Telephone (301) 443-1367.

Committee Name: Treatment Assessment Review Committee.
Meeting Date: March 2-3, 1992.
Place: Embassy Suites, 4300 Military Road, NW, Washington, DC 20015.
Open: March 2, 8:30-9:30 a.m.
Closed: Otherwise.
Contact: Barbara Campbell, room 9C-02, Parklawn Building, Telephone (301) 443-4868.

Committee Name: Child Psychopathology and Treatment Review Committee.
Meeting Date: March 9-11, 1992.
Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.
Open: March 9, 9-10 a.m.
Closed: Otherwise.
Contact: Doris Lee Robb, room 9C-15, Parklawn Building, Telephone (301) 443-6470.

Committee Name: Behavioral, Clinical, and Psychosocial Subcommittee of the Mental Health AIDS and Immunology Review Committee.
Meeting Date: March 11-12, 1992.
Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.
Open: March 11, 8:30-9:30 a.m.
Closed: Otherwise.
Contact: Regina M. Thomas, room 9C-15, Parklawn Building, Telephone (301) 443-6470.

Committee Name: Psychobiological, Biological, and Neuroscience Subcommittee of the Mental Health AIDS and Immunology Review Committee.
Meeting Date: March 11-12, 1992.
Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.
Open: March 11, 8:30-9:30 a.m.
Closed: Otherwise.
Contact: Rehana A. Chowdhury, room 9C-15, Parklawn Building, Telephone (301) 443-6470.

Committee Name: Clinical Subcommittee, Mental Health Special Project Review Committee.
Meeting Date: February 28, 1992.
Place: Holiday Inn Crowne Plaza, 66 Hale Avenue, White Plains, NY 10601.
Open: February 28, 8:30-9 a.m.
Closed: Otherwise.
Contact: Gewn Artis, room 9-C18, Parklawn Building, Telephone (301) 443-3944.

Dated: February 4, 1992.

Peggy W. Cockrill,

Committee Management Officer, Alcohol, Drug Abuse, and Mental Health Administration.

[FR Doc. 91-3024 Filed 2-6-92; 8:45 am]

BILLING CODE 4160-20-M

Centers for Disease Control

National Committee on Vital and Health Statistics (NCVHS) Subcommittee on State and Community Health Statistics: Cancellation of Meeting

This notice announces the cancellation of a previously announced meeting.

Federal Register *Citation of Previous Announcement: 57 FR 3059, January 27, 1992.*

Previously Announced times and Dates: 1 p.m.-5 p.m., February 20, 1992. 9 a.m.-5 p.m., February 21, 1992.